BPC's Comment on FDA's Generative AI-Enabled Medical Devices Discussion Paper (2026 Update)
OVERVIEWThe Bipartisan Policy Center submitted formal comments on FDA's generative AI medical device discussion paper, advocating for balanced regulatory approaches that enable innovation while protecting patient safety. The comments address key policy questions about pre-market validation, post-market surveillance, and adaptive AI governance. Policy Recommendations: BPC recommends FDA establish clear validation standards for generative AI, require ongoing post-market monitoring for adaptive systems, and maintain human oversight requirements for high-stakes clinical decisions. The center advocates for regulatory pathways that differentiate based on clinical risk rather than applying uniform requirements. Regulatory Gaps: Current FDA frameworks inadequately address generative AI's unique characteristics: continuous learning, difficulty predicting failure modes, and need for ongoing validation. BPC's comments highlight tensions between enabling faster patient access to AI tools and ensuring adequate evidence of safety and efficacy before market entry. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.